KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Financing Activities: 2011-2023

Historic Cash from Financing Activities for TherapeuticsMD (TXMD) over the last 12 years, with Dec 2023 value amounting to $2.0 million.

  • TherapeuticsMD's Cash from Financing Activities rose 101.79% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$108.2 million, marking a year-over-year increase of 54.00%. This contributed to the annual value of $3.2 million for FY2023, which is 101.34% up from last year.
  • Per TherapeuticsMD's latest filing, its Cash from Financing Activities stood at $2.0 million for Q4 2023, which was up 200,300.00% from -$1,000 recorded in Q3 2023.
  • TherapeuticsMD's 5-year Cash from Financing Activities high stood at $111.7 million for Q2 2019, and its period low was -$120.0 million during Q2 2022.
  • Its 3-year average for Cash from Financing Activities is -$10.4 million, with a median of $890,500 in 2021.
  • In the last 5 years, TherapeuticsMD's Cash from Financing Activities spiked by 48,669.82% in 2020 and then tumbled by 28,137.38% in 2022.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Cash from Financing Activities stood at $77.0 million in 2019, then plummeted by 58.84% to $31.7 million in 2020, then slumped by 95.73% to $1.4 million in 2021, then crashed by 8,373.84% to -$111.9 million in 2022, then surged by 101.79% to $2.0 million in 2023.
  • Its Cash from Financing Activities was $2.0 million in Q4 2023, compared to -$1,000 in Q3 2023 and -$111.9 million in Q4 2022.